FDA wants to shorten new drug monopolies to cut costs

FDA Commissioner Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines as part of an effort to increase competition and bring down prescription drug prices. Gottlieb said the primary effort is being led by HHS.

FDA Commissioner Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines as part of an effort to increase competition and bring down prescription drug prices. Gottlieb said the primary effort is being led by HHS. "So we’re doing it on the generic side, but we’re also thinking of doing it on the new drug side," Gottlieb said on June 3 at the American Society of Clinical Oncology meeting in Chicago, the world's biggest cancer conference. If companies have breakthrough products and they have invested a lot of capital, they should have an opportunity to price that product based on what the market will bear, Gottlieb said. "They're going to have a monopoly, but that monopoly shouldn't last forever," he said. "That’s what we're trying to facilitate."